Published in:
01-09-2019 | Deep Brain Stimulation | Correction
Correction to: Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies
Published in: Neurological Sciences | Issue 9/2019
Login to get accessExcerpt
Correction to: Neurological Sciences 2019
Table 2
Clinical features of patients according to the treatment after CSAI
|
OTA(n = 58)
|
DBS (n = 34)
|
LCIG (n = 16)
|
Oral vs. DBS
|
DBS vs. LCIG
|
|
|---|---|---|---|---|---|
|
Age at PD onset
|
50 ± 1.6 (31–68)
|
42.16 ± 1.55 (33–58)
|
49.75 ± 1.9 (31–60)
|
<0.001
|
0.029
|
|
Age at CSAI onset
|
61.37 ± 1.22 (41–78)
|
55.29 ± 1.34 (37–67)
|
60.75 ± 2.11 (44–74)
|
0.005
|
NS
|
|
CSAI duration
|
2.29 ± 0.29 (0.5–9)
|
2.39 ± 0.36 (0.5–9.2)
|
3.6 ± 0.61 (0.5–8)
|
NS
|
NS
|
|
MMSE pre-CSAI
|
29.35 ± 0.16 (25–30)
|
29.94 ± 0.58 (28–30)
|
29.62 ± 0.27 (26–30)
|
0.033
|
NS
|
|
MMSE post-CSAI
|
27.7 ± 0.51 (10–30)
|
29.35 ± 0.21 (25–30)
|
27.18 ± 0.61 (22–30)
|
NS
|
NS
|
|
CGI-I
|
2.01 ± 0.83 (1–4)
|
2.29 ± 0.89 (2–4)
|
2.43 ± 0.27 (1–6)
|
NS
|
NS
|
|
CGI-S
|
5.17 ± 0.005 (5–6)
|
5.14 ± 0.61 (5–6)
|
5.31 ± 0.11 (5–6)
|
NS
|
NS
|